Interní Med. 2017; 19(4): 192-197 [Onkologie. 2017:11(3):108-114]

Treatment of elderly and comorbid patients with chronic lymphocytic leukemia

MUDr. Martin Šimkovič, Ph.D., MUDr. Monika Motyčková, Ph.D., MUDr. Pavel Vodárek,, doc. MUDr. Lukáš Smolej, Ph.D.
IV. interní hematologická klinika, Fakultní nemocnice a Univerzita Karlova v Praze, Lékařská fakulta v Hradci Králové

Chronic lymphocytic leukemia (CLL) occurs primarily in the elderly. The high prevalence of serious comorbidities, which mayhave a major impact on the treatment course, is frequent in these patients. Recently, the focus of clinical research in CLL hasbeen shifted on the elderly and comorbid patients. Results of the randomized trials provided us a fundamental improvement oftreatment responses and prolonged overall survival. Chemoimmunotherapy combining chlorambucil with an anti-CD20 antibody(obinutuzumab, ofatumumab a rituximab) is current standard approach for 1st line treatment of elderly/comorbid patients. Bendamustinplus rituximab or dose attenuated FCR are other treatment options. Novel targeted therapy inhibiting B-cell receptorsignaling (ibrutinib and idelalisib) or anti-apoptotic bcl-2 protein (venetoclax) provided a revolutionary therapeutic improvementparticularly in relapsed/refractory CLL. Assessment of performance status, renal function, comorbidities and individual evaluationof patient’s fitness may help us in treatment decision making.

Keywords: chronic lymphocytic leukemia, comorbidity, chemoimmunotherapy, ibrutinib, idelalisib

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šimkovič Monika Motyčková Pavel Vodárek M, Smolej L. Treatment of elderly and comorbid patients with chronic lymphocytic leukemia. Interní Med. 2017;19(4):192-197.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011; 105(11): 1684-1692. Go to original source... Go to PubMed...
    2. Pfeil AM, Imfeld P, Pettengell R, et al. Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD). Ann Hematol. 2015; 94(3): 421-429. Go to original source... Go to PubMed...
    3. Panovska A, Doubek M, Brychtova Y, et al. Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL). Clin Lymphoma Myeloma Leuk. 2010; 10(4): 297-300. Go to original source...
    4. Piccirillo JF, Vlahiotis A, Barrett LB, et al. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol. 2008; 67(2): 124-132. Go to original source... Go to PubMed...
    5. Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, et al. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol. 2005; 129(5): 597-606. Go to original source... Go to PubMed...
    6. Wieringa A, Boslooper K, Hoogendoorn M, et al. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. Br J Haematol. 2014; 165(4): 489-96. Go to original source... Go to PubMed...
    7. Goede V, Cramer P, Busch R, et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica. 2014; 99(6): 1095-100. Go to original source... Go to PubMed...
    8. Bonanad S, De la Rubia J, Gironella M, et al. Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale. J Geriatr Oncol. 2015; 6(5): 353-361. Go to original source... Go to PubMed...
    9. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968; 16(5): 622-626. Go to original source... Go to PubMed...
    10. Parmelee PA, Thuras PD, Katz IR, et al. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc. 1995; 43(2): 130-137. Go to original source... Go to PubMed...
    11. D'Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med. 1993; 32(5): 382-387. Go to original source...
    12. Kobayashi Y, Miura K, Hojo A, et al. Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2011; 137(7): 1079-1084. Go to original source... Go to PubMed...
    13. Lin TL, Kuo MC, Shih LY, et al. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann Hematol. 2012; 91(9): 1383-1391. Go to original source... Go to PubMed...
    14. Singh B, Bhaya M, Stern J, et al. Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study. Laryngoscope. 1997; 107(11 Pt 1): 1469-1475. Go to original source... Go to PubMed...
    15. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985; 33(4): 278-285. Go to original source... Go to PubMed...
    16. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem. 1992; 38(10): 1933-1953. Go to original source...
    17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1): 31-41. Go to original source... Go to PubMed...
    18. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007; 5(4): 345-351. Go to original source... Go to PubMed...
    19. Stauder R, Eichhorst B, Hamaker ME, et al. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Ann Oncol. 2016. Go to original source...
    20. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12): 5446-5456. Go to original source... Go to PubMed...
    21. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014; 370(12): 1101-1110. Go to original source...
    22. Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015; 29(7): 1602-1604. Go to original source... Go to PubMed...
    23. Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015; 385(9980): 1873-1883. Go to original source...
    24. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008; 14(1): 309-317. Go to original source...
    25. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol. 2012; 159(1): 67-77. Go to original source... Go to PubMed...
    26. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009; 27(26): 4378-4384. Go to original source... Go to PubMed...
    27. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011; 29(26): 3559-3566. Go to original source... Go to PubMed...
    28. Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016; 17(7): 928-942. Go to original source...
    29. Michallet AS, Aktan M, Schuh A, et al. Rituximab in combination with bendamustine or chlorambucil for the treatment of chronic lymphocytic leukemia: primary results from the randomised phase IIIb MABLE study. Leuk Lymphoma. 2015; 56: 149.
    30. Stilgenbauer S, Ilhan O, Woszczyk D, et al. Safety and Efficacy of Obinutuzumab Plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the Green Study. Blood. 2015; 126(23): 493. Go to original source...
    31. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002; 43(9): 1755-1762. Go to original source...
    32. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002; 99(10): 3554-3561. Go to original source...
    33. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004; 103(9): 3278-3281. Go to original source...
    34. Osterborg A, Foa R, Bezares RF, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia. 2009; 23(11): 1980-1988. Go to original source... Go to PubMed...
    35. Osuji NC, Del Giudice I, Matutes E, et al. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica. 2005; 90(10): 1435-1436. Go to PubMed...
    36. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010; 28(10): 1749-1755. Go to original source... Go to PubMed...
    37. Wierda WG, Padmanabhan S, Chan GW, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011; 118(19): 5126-5129. Go to original source...
    38. Castro JE, Sandoval-Sus JD, Bole J, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia. 2008; 22(11): 2048-2053. Go to original source... Go to PubMed...
    39. Dungarwalla M, Evans SO, Riley U, et al. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica. 2008; 93(3): 475-476. Go to original source... Go to PubMed...
    40. Castro JE, James DF, Sandoval-Sus JD, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia. 2009; 23(10): 1779-1789. Go to original source... Go to PubMed...
    41. Pileckyte R, Jurgutis M, Valceckiene V, et al. Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Leuk Lymphoma. 2011; 52(6): 1055-1065. Go to original source...
    42. Simkovic M, Motyckova M, Belada D, et al. Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia. Arch Med Sci. 2016; 12(2): 421-427. Go to original source...
    43. Smolej L, Doubek M, Panovska A, et al. Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2012; 36(10): 1278-1282. Go to original source...
    44. Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol. 2013; 31(1): 128-130. Go to original source... Go to PubMed...
    45. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371(3): 213-223. Go to original source...
    46. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 373(25): 2425-2437. Go to original source... Go to PubMed...
    47. Barr P, Robak T, Owen CJ, et al. Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Blood. 2016; 128(22): 234. Go to original source...
    48. Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015; 29(4): 783-787. Go to original source...
    49. Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014; 124(26): 3991-3995. Go to original source...
    50. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370(11): 997-1007. Go to original source...
    51. Souhrn údajů o přípravku Zydelig. [online].[cit. 5-4-2017]. Dostupné z: http://wwwemaeuropaeu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/003843/WC500175377pdf.
    52. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015. Go to original source...
    53. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016; 374(4): 311-322. Go to original source...
    54. Jones J, Choi MY, Mato AR, et al. Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. Blood. 2016; 128(22): 637. Go to original source...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.